Rhythm Pharmaceuticals Incis A Biopharmaceutical Company Based In Bostonmassachusettsfounded In 2008It Focuses On Developing Precision Medicines For Rare Neuroendocrine Diseasesparticularly Those Related To The Melanocortin 4 Receptormc4Rpathwaythe Company Became Publicly Traded On The Nasdaq In 2017 And Employs Over 250 People Across North America And Europe The Company S Mission Is To Improve The Lives Of Patients With Rare Mc4R Pathway Diseases By Creating Targeted Therapiesits Flagship Productimcivreea Setmelanotide Is Fda Approved For Treating Severe Obesity And Hyperphagia Linked To Mc4R Pathway Impairmentsrhythm Pharmaceuticals Is Also Advancing A Pipeline Of Investigational Therapiesincluding Bivamelagon For Acquired Hypothalamic Obesity And Rm 718Designed To Minimize Side Effectsthe Company Operates In The U S Canadajapanand Several European Countriesfocusing On Patientsfamiliesand Healthcare Providers Involved In Managing These Conditions
